Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 9/20 | 0.42 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 6/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 6/20 | 0.37 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25313988 | 0.91 | MAP3K5 (0.42) | MAP3K5PDCD1CD274 | |
| SCHEMBL24127335 | 0.91 | MAP3K5 (0.42) | MAP3K5PDCD1CD274 | |
| SCHEMBL30596005 | 0.91 | MAP3K5 (0.42) | MAP3K5PDCD1CD274 | |
| SCHEMBL25312939 | 0.90 | PDCD1 (0.47) | MAP3K5PDCD1CD274PRMT5WDR77 | |
| SCHEMBL30389787 | 0.90 | PDCD1 (0.47) | MAP3K5PDCD1CD274PRMT5WDR77 | |
| SCHEMBL24127439 | 0.90 | PDCD1 (0.47) | MAP3K5PDCD1CD274PRMT5WDR77 | |
| SCHEMBL30595971 | 0.89 | MAP3K5 (0.40) | MAP3K5PDCD1CD274PRMT5WDR77 | |
| SCHEMBL24127327 | 0.89 | MAP3K5 (0.40) | MAP3K5PDCD1CD274PRMT5WDR77 | |
| SCHEMBL30595962 | 0.87 | PRMT5 (0.42) | MAP3K5PDCD1CD274PRMT5WDR77 | |
| SCHEMBL24127333 | 0.87 | PRMT5 (0.42) | MAP3K5PDCD1CD274PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234970-A1 | IMMUNOSUPPRESSANT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234970-A1 | IMMUNOSUPPRESSANT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CD274, PDCD1, PDCD1LG2 | MAP3K5 341/4885PDCD1 2/4885CD274 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.